USV Pvt Ltd
About
USV was founded by Vithal Balkrishna Gandhi. Currently, his granddaughter, Leena Tewari, serves as the company's chairperson and Prashant Tewari holds the position of MD. The establishment is a 62 year old leading healthcare company which began as a joint venture with USV & P Inc. USA, a subsidiary of Revlon. The range of products include Active Pharmaceutical Ingredients (APIs), Fixed Dosages Formulations (FDF), Peptides, Biosimilars and Injectables. These are manufactured in the company’s cGMP compliant plants located in India. The products are shipped globally to 65+ countries. USV’s intellectual property portfolio consists of patent filings for 15 inventions of which 12 have been granted. All manufacturing sites are ISO-14001 and OHSAS 18001 certified thus conforming to world Environment, Health and Safety standards.
Featured In Fortune India Ranking
Financial Data 2024
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 4825 12.1% | 4305 5.8% | 4069 7.2% | 3796 14.9% | 3303 5.9% | 3120 10.0% | 2837 2.2% | 2775 7.7% | 2577 18.2% | 2180 8.6% | 2008 14.5% | 1755 15.5% | 1519 24.0% | 1225 15.1% | 1064 18.8% | 896 - |
| Net Operating Income (INR Cr) | 4553 9.55% | 4156 6.74% | 3893 6.69% | 3649 0.00% | 3141 5.26% | 2984 9.47% | 2726 4.04% | 2620 9.97% | 2383 14.77% | 2076 9.75% | 1891 11.99% | 1689 16.69% | 1447 26.47% | 1144 12.75% | 1015 21.24% | 837 24.43% |
| Profit (INR Cr) | 1377 19.7% | 1151 6.6% | 1080 4.3% | 1036 28.9% | 803 8.0% | 744 53.9% | 484 -19.8% | 603 2.0% | 591 33.4% | 443 -7.3% | 478 29.1% | 371 31.2% | 282 10.9% | 255 15.4% | 221 27.9% | 173 - |
| Assets (INR Cr) | 5484 17.4% | 4673 11.5% | 4189 10.4% | 3796 30.5% | 2909 1.4% | 2870 9.0% | 2634 22.2% | 2156 11.9% | 1927 20.8% | 1595 7.7% | 1481 18.0% | 1255 8.5% | 1157 14.5% | 1010 10.7% | 913 8.2% | 844 - |
| Net Worth (INR Cr) | 5298 17.4% | 4513 11.7% | 4041 9.9% | 3677 0.0% | 2759 0.5% | 2745 9.3% | 2512 23.4% | 2035 13.1% | 1800 13.3% | 1589 7.6% | 1477 18.1% | 1251 16.1% | 1077 7.0% | 1007 10.8% | 909 8.3% | 839 2.8% |
| Employee Cost (INR Cr) | 726 24.9% | 581 11.8% | 520 4.9% | 495 18.1% | 419 17.7% | 356 13.0% | 315 11.0% | 284 14.6% | 248 22.2% | 203 5.6% | 192 24.2% | 155 4.8% | 148 52.6% | 97 28.9% | 75 29.8% | 58 - |
| Interest Cost (INR Cr) | 3 | 3 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 3 | 0 | 0 | 0 |
| Cash & Bank Balance (INR Cr) | 123 | 224 | 221 | 261 | 96 | 94 | 100 | 82 | 84 | 67 | 96 | 72 | 40 | 101 | 75 | 288 |
| Total Debt (INR Cr) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 3 | 3 | 4 | 5 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 28.6% | 26.7% | 26.5% | 27.3% | 24.3% | 23.9% | 17.0% | 21.7% | 23.0% | 20.3% | 23.8% | 21.1% | 18.6% | 20.8% | 20.8% | 19.3% |
| Profit As % Of Assets | 25.1% | 24.6% | 25.8% | 27.3% | 27.6% | 25.9% | 18.4% | 28.0% | 30.7% | 27.8% | 32.3% | 29.5% | 24.4% | 25.2% | 24.2% | 20.5% |
| Profit As % Of Networth | 26.0% | 25.5% | 26.7% | 28.2% | 29.1% | 27.1% | 19.3% | 29.6% | 32.9% | 27.9% | 32.4% | 29.6% | 26.2% | 25.3% | 24.3% | 20.6% |
| Interest Cost to EBITDA % | 0.2% | 0.2% | 0.1% | 0.1% | 0.2% | - | - | - | - | - | - | 0.6% | 0.8% | 0.1% | 0.1% | 0.3% |
| Debt to Equity Ratio | - | - | - | - | - | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| RONW | 28.1% | 26.9% | 28.0% | 28.2% | 25.2% | 28.3% | 21.3% | 27.5% | 30.4% | 24.4% | 35.1% | 27.4% | 22.9% | 26.6% | 25.3% | 17.0% |
| ROCE | 35.2% | 34.4% | 36.6% | 36.9% | 32.0% | 38.2% | 34.6% | 33.0% | 36.2% | 30.8% | 39.9% | 29.8% | 27.4% | 27.8% | 30.3% | 18.9% |